Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis

Indian Journal of Endocrinology and Metabolism

Volumn 19, Issue 4, 2015, Pages 524-528

  Kalra, Sanjay ^a   Sahay, Rakesh ^b   Gupta, Yashdeep ^c  

^a Bharti Hospital and BRIDE   (India)

^b OSMANIA MEDICAL COLLEGE   (India)

^c GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Canagliflozin; dapagliflozin; empagliflozin; good clinical sense; ketoacidosis; ketonuria; type 1 diabetes; type 2 diabetes

Indexed keywords

EID: 84981289630     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.157859     Document Type: Article

References (22)

1. Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412-9.
2. Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: Results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480-3.
3. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-97.
4. Bell DS. Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient. Case Rep Endocrinol 2015;2015:676191.
5. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28.
6. Molina-Jijon E, Rodriguez-Munoz R, Namorado Mdel C, Pedraza-Chaverri J, Reyes JL. Oxidative stress induces claudin-2 nitration in experimental type 1 diabetic nephropathy. Free Radic Biol Med 2014;72:162-75.
7. Cherney DZ, Perkins BA. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: Simultaneous glucose lowering and renal protection-Can J Diabetes 2014;38:356-63.
8. Skrtic M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014;57:2599-602.
9. Dutta D, Kalra S. Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice. J Pak Med Assoc 2014;64:1203-6.
10. Hayami T, Kato Y, Kamiya H, Kondo M, Naito E, Sugiura Y, et al. A case of ketoacidosis by a SGLT2 inhibitor in a diabetic patient with low carbohydrate diet. J Diabetes Investig 2015. DOI: 10.1111/ jdi.12330. [Last accessed on 2015 Feb 20].
11. Goldblatt MW. Observations on the effect of various carbohydrates on the ketosis of starvation in human subjects. Biochem J 1925;19:948-57.
12. EHRSTRöM R. Wassermangel der Gewebe und Ausscheidung von Azetonkörpern. Acta Medica Scandinavica, 1922;56:507-9. doi: 10.1111/j.0954-6820.1922.tb18501.x [article in German].
13. Freund G. The calorie deficiency hypothesis of ketogenesis tested in man. Metabolism 1965;14:985-90.
14. Mahoney CA. Extreme gestational starvation ketoacidosis: Case report and review of pathophysiology. Am J Kidney Dis 1992;20:276-80.
15. Burr K, Nguyen AT, Rasouli N. SAT-595: A Case Report of Ketoacidosis Associated with Canagliflozin (Invokana). Available at: http://press.endocrine.org/doi/abs/10.1210/endo-meetings. 2015. DGM.5.SAT-595. [Last accessed on 2015 May 17].
16. Peters JP. Starvation diabetes, the reason for the use of glucose in the treatment of diabetic acidosis. The Yale journal of biology and medicine 1945;17:705.
17. Kelwade J, Sethi BK, Nagesh SV, Vaseem A. A case of "pseudo-ketoacidosis". Indian J Endocrinol Metab 2014;18:743.
18. Mills SE, Lyle RR, Beitz DC, Young JW. In vitro hepatic gluconeogenesis during experimental ketosis produced in steers by 1,3-butanediol and phlorizin. J Dairy Sci 1984;67:2265-73.
19. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available from: http://www.fda.gov/Drugs/DrugSafety/ ucm446845.htm. [Last accessed on 2015 May 17].
20. Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr 2006;26:1-22.
21. Kalra S, Gupta Y, Patil S. Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions. Indian J Endocrinol Metab 2015;19:426-9.
22. Johnston DG, Blesa-Malpica G, Burrin JM, Waugh C, Cook D, Orskov H, et al. Dopamine blockade inhibits starvation ketosis in man. Clin Endocrinol (Oxf) 1983;19:389-96.